Prestige Biologics

At a glance

Prestige Biologics filed 38 disclosures in the last 12 months, including 6 contract, 2 insider and 1 5% holder. The most recent key filing was on Jul 10.

Revenue for 2025 was ₩12.5B, up 477.8% on 2024. It made an operating loss of ₩33.7B. Debt was 100% of equity at year end.

The 2025 annual report lists 279 employees with an average tenure of 2.1 years and average pay of ₩42.2M, #2035 of 2,191 listed companies by average pay. Its 8 directors and auditors were paid ₩125.7M each on average. It paid no cash dividend for 2025. 프레스티지바이오파마 and related parties held 60.22% at year end.

Of 1 recent 5%+ holder report, 1 raised and 0 cut a stake; the largest stake reported was 60.37% on Jul 10.

From the 2025 annual report

Staff: 279 (138 men, 141 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩10.2B. Directors and auditors: 8, paid ₩353.2M in total.

No cash dividend was paid for 2025.

Largest shareholder

프레스티지바이오파마 holds 40.03%; with 5 related parties the group holds 60.22% of common shares at year end (from 50.34% at the start of the year).

Auditor: 삼덕회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

New contracts, last 12 months

2 new supply contracts worth 42% of the revenue stated in the filings.

Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.

Financial summary

5%+ holder reports